Genmab Commences Binding Arbitration of Two Matters Under License Agreement with Janssen

Source :: ICT Monitor Worldwide. September 23, 2020
Publication Year :: 2020
Abstract: (GlobeNewswire) - Company Announcement Copenhagen, Denmark; September 22, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it has commenced binding arbitration of two matters arising under its license agreement with [...]

Subjects :: Genmab A/S -- Negotiation, mediation and arbitration -- Licensing agreements
Hyaluronidase -- Licensing agreements
Daratumumab
Ofatumumab -- Licensing agreements
Company licensing agreement
Telecommunications industry
Darzalex (Medication) -- Licensing agreements

Tools